These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25317080)

  • 1. Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia.
    Bai J; He A; Huang C; Yang J; Zhang W; Wang J; Yang Y; Zhang P; Zhang Y; Zhou F
    Proteome Sci; 2014; 12(1):49. PubMed ID: 25317080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling.
    Bai J; He A; Zhang W; Huang C; Yang J; Yang Y; Wang J; Zhang Y
    Proteome Sci; 2013; 11():39. PubMed ID: 23915341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Identification of serum biomarkers for assessing minimal residual disease in acute leukemia by serum peptide pattern].
    Song W; Li W; Wang GJ; Wang N; Liang TT; Li Y; Cui JW
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):714-8. PubMed ID: 23978027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma.
    Bai J; Yang Y; Wang J; Zhang L; Wang F; He A
    Clin Proteomics; 2019; 16():17. PubMed ID: 31043929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia.
    Song W; Wang N; Li W; Wang G; Hu J; He K; Li Y; Meng Y; Chen N; Wang S; Hu L; Xu B; Wang J; Li A; Cui J
    Oncol Lett; 2013 Nov; 6(5):1453-1460. PubMed ID: 24179540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
    Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
    Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoform 1 of Fibrinogen Alpha Chain Precursor is a Potential Biomarker for Steroid-Induced Osteonecrosis of the Femoral Head.
    Liu L; Song J; Li J; Huang N; Yang J; Hu S; Ma R; Wang W
    Proteomics Clin Appl; 2020 Nov; 14(6):e1900099. PubMed ID: 32677377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of biomarkers for endometriosis using clinical proteomics.
    Zhao Y; Liu YN; Li Y; Tian L; Ye X; Cui H; Chang XH
    Chin Med J (Engl); 2015 Feb; 128(4):520-7. PubMed ID: 25673457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Establishment of diagnostic model to monitor minimal residual disease of acute promyelocytic leukemia by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry].
    Zhang LL; Xu ZF; Tan YH; Chen XH; Xu AN; Ren FG; Wang HW
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):16-20. PubMed ID: 23597458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.
    Inoue K; Sugiyama H; Ogawa H; Nakagawa M; Yamagami T; Miwa H; Kita K; Hiraoka A; Masaoka T; Nasu K
    Blood; 1994 Nov; 84(9):3071-9. PubMed ID: 7949179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
    J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptidome profiling of umbilical cord plasma associated with gestational diabetes-induced fetal macrosomia.
    Liu F; Zhao C; Liu L; Ding H; Huo R; Shi Z
    J Proteomics; 2016 Apr; 139():38-44. PubMed ID: 26945739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment.
    Liang T; Wang N; Li W; Li A; Wang J; Cui J; Liu N; Li Y; Li L; Yang G; Du Z; Li D; He K; Wang G
    Proteomics; 2010 Jan; 10(1):90-8. PubMed ID: 19882663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant Phenotype and Function of Dendritic Cells in Adult B Lineage Acute Lymphoblastic Leukemia.
    Zhou Z; Lin W; Li X; Huang Y; Ren J; Gao Y; Li J
    Immunol Invest; 2019 Nov; 48(8):781-793. PubMed ID: 31062637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
    Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
    Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
    Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
    Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N; Kantarjian HM; Brüggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M; O'Brien S; Zugmaier G; Gao S; Nagorsen D; Forman SJ; Topp MS
    Blood Adv; 2019 Oct; 3(20):3033-3037. PubMed ID: 31648325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
    den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
    Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.